Page 197 - 2019_12-Haematologica-web

Hypertensive emergency and hemolytic uremic syndrome
14. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recom- mendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
15. Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539-551.
16. Foster MC, Coresh J, Fornage M, et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol. 2013;24(9):1484-1491.
17. Kremer Hovinga JA, Heeb SR, Skowronska M, Schaller M. Pathophysiology of throm- botic thrombocytopenic purpura and hemolytic uremic syndrome. J Thromb Haemost. 2018;16(4):618-629.
18. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, et al. The development of atypical haemolytic-uraemic syndrome is influenced
by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet. 2005;42(11):852-856.
19. Osborne AJ, Breno M, Borsa NG, et al. Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syn- drome and C3 glomerulopathy. J Immunol. 2018;200(7):2464-2478.
20. Mathew RO, Nayer A, Asif A. The endothe- lium as the common denominator in malig- nant hypertension and thrombotic microan- giopathy. JASH. 2016;10(4):352-359.
21. Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier CT, Jr. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol. 2003;14(8):1990-1997.
22. Negishi E, Fukuda N, Otsuki T, et al. Involvement of complement 3 in the salt- sensitive hypertension by activation of renal renin-angiotensin system in spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2018;315(6):F1747-f1758.
23. Bekassy ZD, Kristoffersson AC, Rebetz J, Tati R, Olin AI, Karpman D. Aliskiren inhibits renin-mediated complement activa- tion. Kidney int. 2018;94(4):689-700.
24. Raghunathan V, Sethi SK, Dragon-Durey MA, et al. Targeting renin-angiotensin sys- tem in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017;27(2):136-140.
25. van den Born BJ, Koopmans RP, van Montfrans GA. The renin-angiotensin sys- tem in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. Am J Hypertens. 2007;20 (8):900-906.
26. Romagnani P, Remuzzi G, Glassock R, et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3:17088.
27. Fakhouri F, Fila M, Provot F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syn- drome relapse after eculizumab discontin- uation. Clin J Am Soc Nephrol. 2017;12(1) :50-59.
haematologica | 2019; 104(12)
2511